DEFA14A: ZimVie Announces Definitive Agreement for Acquisition by ARCHIMED Affiliate

ZimVie Inc. has entered into a definitive agreement to be acquired by Zamboni Parent, Inc., an affiliate of ARCHIMED, a private equity firm focused on healthcare industries.

Summary

• ZimVie Inc. has signed a definitive agreement to be acquired by Zamboni Parent, Inc., an affiliate of ARCHIMED.
• ARCHIMED is a global private equity group specializing in healthcare industries, with a portfolio spanning biotech, consumer health, diagnostics, life sciences, MedTech, animal and environmental health.
• The transaction is expected to close by the end of 2025, subject to ZimVie stockholder approval and required regulatory clearances.
• Post-acquisition, ZimVie is expected to operate independently as a standalone business, retaining its brand, existing infrastructure, team members, facilities, manufacturing, and systems.
• Management believes the acquisition is in the best interest of the company, shareholders, and team members, providing investment for innovation and accelerated growth.

Sentiment

Score: 8

Explanation: The filing conveys a highly positive sentiment regarding the acquisition, emphasizing strategic benefits, growth opportunities, and minimal immediate disruption for employees and customers. Management expresses strong confidence in the future under ARCHIMED. The primary caveats are standard M&A risks, not inherent negatives of the deal itself.

Positives

• The acquisition by ARCHIMED is expected to provide necessary investment to innovate and accelerate ZimVie's growth.
• ARCHIMED brings a mix of operational, medical, scientific, and financial expertise, serving as both a strategic and financial partner.
• ZimVie is expected to maintain its independent operation as a standalone business, preserving its brand and existing infrastructure.
• No immediate changes are anticipated for employee roles, responsibilities, benefits, or compensation.
• Current priority initiatives, such as Oracle Cloud implementation and the Big Bang project, will continue as planned.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to receive required approvals from ZimVie's stockholders.
• Failure to satisfy or waive various conditions to the consummation of the proposed transaction, including regulatory approvals.
• The possibility that competing offers or acquisition proposals for ZimVie will be made.
• The occurrence of any event, change, or circumstance that could lead to the termination of the definitive transaction agreement, potentially requiring ZimVie to pay a termination fee.
• Potential negative effects of the announcement or pendency of the proposed transaction on ZimVie's ability to attract, motivate, or retain key executives and employees.
• Potential negative effects on ZimVie's ability to maintain relationships with its customers, suppliers, and other business counterparties, or its operating results and business generally.
• Risks related to the proposed transaction diverting management's attention from ongoing business operations.
• Risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay.
• Other risks discussed in ZimVie's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

ZimVie expects the acquisition by ARCHIMED to close by the end of 2025, pending stockholder and regulatory approvals. Post-closing, ZimVie anticipates operating independently as a standalone business, maintaining its brand and existing infrastructure, with ARCHIMED serving as a strategic and financial partner to accelerate growth and innovation.

Management Comments

• Vafa Jamali, President, Chairman and CEO: "We believe this decision is in the best interest of our Company, our shareholders, and our team members, and will enable us to fully achieve our key objectives: growth, innovation, and operational excellence through a new investment lens."
• Vafa Jamali, President, Chairman and CEO: "I have every reason to be confident in our future under ARCHIMED and thank you for your continued commitment to our success."
• Jordi Carmona, VP of International Markets: "I am excited about this news and the opportunity it brings for our business, our customers, and the patients we serve."
• Jordi Carmona, VP of International Markets: "Im extremely optimistic about our future under ARCHIMED and thank you for your continued commitment to our success."
• Scott Beaudean, VP of the Americas: "I am excited about this news and the opportunity it brings for our business, our customers, and the patients we serve."
• Scott Beaudean, VP of the Americas: "Im extremely optimistic about our future under ARCHIMED and thank you for your continued commitment to our success."

Industry Context

This acquisition highlights the continued interest of private equity firms, particularly those with specialized healthcare focus like ARCHIMED, in the MedTech and broader healthcare sectors. Such transactions often aim to provide capital and strategic expertise to accelerate growth and innovation for companies in a private setting, away from public market pressures.

Stakeholder Impact

• Shareholders: The Board believes the transaction is in their best interest, and their approval is required for the deal to close.
• Employees: Expected to experience little to no change in day-to-day roles, responsibilities, benefits, or compensation in the near-term. ARCHIMED intends to leverage existing personnel and infrastructure.
• Customers: No anticipated changes in brands or customer support, with sales teams provided communication tools to discuss the news.
• Suppliers: ZimVie's ability to maintain relationships with suppliers is identified as a risk if the transaction's pendency negatively impacts operations.

Next Steps

• ZimVie intends to file relevant materials with the SEC, including a proxy statement in preliminary and definitive form, in connection with the proposed transaction.
• ZimVie stockholders are urged to read all relevant documents filed with the SEC, including the proxy statement, when available.
• The transaction requires ZimVie stockholder approval and regulatory clearances.
• The deal is expected to close by the end of 2025.
• ZimVie will continue to operate business as usual, separately from ARCHIMED, until the deal closes.
• Management will communicate regularly about any changes taking place when relevant, particularly to impacted team members, customers, and partners.
• ARCHIMED will evaluate business needs and may make adjustments to the current organization if necessary, with required consultation procedures.

Key Dates

Recommendation

The filing announces a definitive acquisition agreement, which typically leads to a 'hold' recommendation for existing shareholders awaiting the completion of the transaction. While the board believes the deal is in the 'best interest' of shareholders, the specific acquisition price is not disclosed in this filing, preventing a definitive 'buy' or 'sell' recommendation based on potential arbitrage or premium. For new investors, a 'hold' or 'NA' is appropriate until the acquisition terms (e.g., per-share price) are fully disclosed and evaluated against current market price.

Keywords

MedTech, healthcare, acquisition, private equity, corporate governance, merger, SEC filing, ZimVie, ARCHIMED, Zamboni Parent